Anika Therapeutics vs Bioventus
ANIK and BVS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANIK and BVS compare
Bioventus is the larger company, worth 5.0 times as much as Anika Therapeutics ($924M against $187M).
Anika Therapeutics grew revenue faster over the last twelve months (9.4% versus 3.9% for Bioventus).
Bioventus keeps more of each dollar of sales as profit, with a net margin of 9.8% compared with −1.4% at Anika Therapeutics.
Bioventus scores higher on the StockData Score (14 against 12 for Anika Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANIK | BVS |
|---|---|---|
| Size and price | ||
| Market cap | $187M | $924M |
| Share price | $13.95 | $10.99 |
| Change, 1 year | 38.5% | 46.7% |
| Change, 5 years | −65.2% | −21.6% |
| Beta (5Y) | 0.86 | 0.91 |
| Employees | 235 | 930 |
| StockData Score | ||
| Total score | 12 | 14 (better) |
| Valuation score | 1 | 4 (better) |
| Growth score | 2 | 3 (better) |
| Performance score | 3 | 5 (better) |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 13.7× |
| P/S | 1.5× (better) | 1.6× |
| P/B | 1.4× (better) | 3.8× |
| EV/EBITDA | 46.2× | 14.4× (better) |
| P/FCF | 81.3× | 10.9× (better) |
| FCF yield | 1.2% | 9.2% (better) |
| Fair value | $12.68 | $16.36 |
| Margin of safety | −10.0% | 32.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 9.4% (better) | 3.9% |
| Revenue growth, 5Y average | −2.9% | 12.1% (better) |
| Net income growth (TTM) | – | 655% |
| EPS growth (TTM) | – | 627% |
| Profitability | ||
| Gross margin | 63.4% | 68.7% (better) |
| Operating margin | −2.1% | 9.7% (better) |
| Net margin | −1.4% | 9.8% (better) |
| FCF margin | 1.9% | 14.5% (better) |
| Return on equity | −1.2% | 28.2% (better) |
| Return on invested capital | −2.6% | 12.8% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.96 (better) |
| Net debt / EBITDA | – | 2.44 |
| Current ratio | 3.86 (better) | 1.68 |
| Altman Z-score | 3.68 (better) | 2.19 |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | 8.1% (better) | −0.31% |
| Shareholder yield | 8.1% (better) | −0.31% |
| Ownership | ||
| Held by institutions | 91.9% | 71.2% |
| Held by insiders | 16.9% | 29.0% |
| Insider net buying, 12 months | $264K (better) | −$181K |
| Short interest, % of float | 2.9% | 5.1% |
Go deeper
- ANIK stock overview
- ANIK income statement
- ANIK valuation and score
- BVS stock overview
- BVS income statement
- BVS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.